arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Enliven Therapeutics, Inc.

ELVN Health Care Biotechnology: Pharmaceutical Preparations
$41.52
▼ -0.7% Today
as of Oct 23, 16:48 ET
Last 30 days -23.72% Sep 14 → Oct 23
$35.95 $40.91 $45.88 $50.84 $55.80 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$41.49
High
$41.64
Low
$40.82
Volume
$2M
Avg Vol
$1M
Mkt Cap
$3.4B
P/E (TTM)
—
Beta
—
52w High
$62.32
52w Low
$14.79
Div Yield
—
Shares Out
$73M

Recent Press Releases & News last 60 days · 11 items

Oct 14 · 20:30 PR PR Newswire
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Oct 10 · 04:20 Simply Wall St.
Why Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML Strategy
Oct 7 · 15:21 BioPharma Dive
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
▸ Show all 11 press releases & news Free account →

ELVN earnings at a glance

The options market is pricing a move of about ±7.8% after the report, a range of roughly $38.30 to $44.74 from today's $41.52. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±1.5% on average; after the most recent report on May 7, 2026 it moved -2.2%. That means options currently expect more movement than ELVN has typically delivered. ELVN beat the consensus EPS estimate in 3 of its last 4 reported quarters. Implied volatility is currently 66%. The share price of $41.52 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$15
$62
56% of range
Avg surprise (last 4)
+8.8%
Avg reaction (last 2)
-1.5%
0% positive
Latest IV / EM
66%
EM ±7.8% · $40 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.80$-0.68$-0.56$-0.44$-0.32 Actual $-0.80Actual $-0.41Actual $-0.51Actual $-0.54Actual $-0.41Actual $-0.48Actual $-0.57Est $-0.51Actual $-0.49Est $-0.53Actual $-0.32Est $-0.43Actual $-0.38Est $-0.44Actual $-0.49 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-32M$-30M$-27M$-24M$-21M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.49 — — — — financials
Thu May 7, 2026Mar/2026 $-0.38 $-0.44 +13.6% +33.3% -2.2% earnings
Wed Nov 12, 2025Sep/2025 $-0.32 $-0.43 +25.6% — — earnings
Wed Aug 13, 2025Jun/2025 $-0.49 $-0.53 +7.5% — — earnings
Wed May 14, 2025Mar/2025 $-0.57 $-0.51 -11.8% — -0.7% earnings
Mon Sep 30, 2024Sep 2024 $-0.48 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.41 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.54 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.51 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.41 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.80 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-37M$-28M—$-25M$-29M$-32M—$-27M
Net income$-32M$-24M—$-20M$-25M$-29M—$-23M
EPS (diluted)$-0.49$-0.38—$-0.32$-0.49$-0.57—$-0.48

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$136M$132M$99M$102M$119M$102M$124M$101M
Inventory————————
Total current assets$907M$463M$475M$483M$496M$294M$318M$297M
Total assets$910M$465M$476M$491M$504M$303M$326M$305M
Long-term debt————————
Total liabilities$15M$11M$17M$15M$15M$14M$16M$17M
Total equity$895M$453M$460M$476M$488M$288M$310M$288M

Implied volatility — last 90 days

47%103%158%214%269% Jun 07 — IV 250% · EM ±34.6%Jun 08 — IV 243% · EM ±32.1%Jun 09 — IV 264% · EM ±33.1%Jun 10 — IV 270% · EM ±31.9%Jun 11 — IV 100% · EM ±11.0%Jun 12 — IV 86% · EM ±8.8%Jun 15 — IV 144% · EM ±10.4%Jun 16 — IV 156% · EM ±9.2%Jun 17 — IV 169% · EM ±7.1%Jun 19 — IV 67% · EM ±14.9%Jun 22 — IV 76% · EM ±15.9%Jun 23 — IV 72% · EM ±14.8%Jun 24 — IV 74% · EM ±14.8%Jun 25 — IV 70% · EM ±13.8%Jun 26 — IV 67% · EM ±12.7%Jun 29 — IV 71% · EM ±12.5%Jun 30 — IV 70% · EM ±12.1%Jul 01 — IV 80% · EM ±13.3%Jul 02 — IV 74% · EM ±12.0%Jul 03 — IV 77% · EM ±12.0%Jul 06 — IV 75% · EM ±10.4%Jul 07 — IV 63% · EM ±8.3%Jul 08 — IV 72% · EM ±9.0%Jul 09 — IV 70% · EM ±8.2%Jul 10 — IV 78% · EM ±8.7%Jul 13 — IV 84% · EM ±7.0%Jul 14 — IV 138% · EM ±10.0%Jul 15 — IV 197% · EM ±11.7%Jul 16 — IV 125% · EM ±5.2%Jul 20 — IV 70% · EM ±16.5%Jul 21 — IV 66% · EM ±15.3%Jul 22 — IV 65% · EM ±14.9%Jul 23 — IV 66% · EM ±14.9%Jul 24 — IV 64% · EM ±14.2%Jul 27 — IV 68% · EM ±14.3%Jul 28 — IV 67% · EM ±13.7%Jul 29 — IV 68% · EM ±13.7%Jul 30 — IV 66% · EM ±13.0%Jul 31 — IV 54% · EM ±10.4%Aug 03 — IV 84% · EM ±14.8%Aug 04 — IV 78% · EM ±13.5%Aug 05 — IV 79% · EM ±13.2%Aug 06 — IV 67% · EM ±10.9%Aug 07 — IV 57% · EM ±8.9%Aug 10 — IV 65% · EM ±9.0%Aug 11 — IV 74% · EM ±9.8%Aug 12 — IV 73% · EM ±9.1%Aug 13 — IV 73% · EM ±8.6%Aug 14 — IV 77% · EM ±8.5%Aug 17 — IV 80% · EM ±6.7%Aug 18 — IV 68% · EM ±4.9%Aug 19 — IV 72% · EM ±4.3%Aug 20 — IV 88% · EM ±3.7%Aug 24 — IV 56% · EM ±11.7%Aug 25 — IV 54% · EM ±11.0%Aug 26 — IV 55% · EM ±11.1%Aug 27 — IV 56% · EM ±11.0%Aug 28 — IV 56% · EM ±10.8%Aug 31 — IV 66% · EM ±11.7%Sep 01 — IV 65% · EM ±11.2%Sep 02 — IV 57% · EM ±9.5%Sep 03 — IV 57% · EM ±9.2%Sep 04 — IV 57% · EM ±8.8%Sep 07 — IV 64% · EM ±8.8%Sep 08 — IV 66% · EM ±8.7%Sep 09 — IV 93% · EM ±11.7%Sep 10 — IV 51% · EM ±6.0%Sep 11 — IV 60% · EM ±6.6%Sep 14 — IV 67% · EM ±5.6%Sep 15 — IV 69% · EM ±5.0%Sep 16 — IV 121% · EM ±7.1%Sep 21 — IV 53% · EM ±11.2%Sep 22 — IV 58% · EM ±11.8%Sep 23 — IV 50% · EM ±10.0%Sep 24 — IV 47% · EM ±9.3%Sep 25 — IV 53% · EM ±10.2%Sep 28 — IV 60% · EM ±10.6%Sep 29 — IV 58% · EM ±10.0%Sep 30 — IV 77% · EM ±12.9%Oct 01 — IV 80% · EM ±13.0%Oct 02 — IV 88% · EM ±13.7%Oct 05 — IV 99% · EM ±13.8%Oct 06 — IV 105% · EM ±13.9%Oct 07 — IV 84% · EM ±10.5%Oct 08 — IV 66% · EM ±7.8%

Sector peers

IDYA
IDEAYA Biosciences, Inc.
$3.5B $34.71-2.1%
RCUS
Arcus Biosciences, Inc.
$3.1B $18.54-2.9%
TNGX
Tango Therapeutics, Inc.
$3.7B $23.34-13.5%
DYN
Dyne Therapeutics, Inc.
$3.0B $15.62-2.8%
CPRX
Catalyst Pharmaceuticals, Inc.
$3.9B $31.49
TLX
Telix Pharmaceuticals Limited
$3.9B $9.15-8.8%

ELVN earnings FAQ

What is ELVN's expected move for earnings?

Options currently price a move of about ±7.8%, or $3.22 per share either way from $41.52.

How does ELVN stock usually react to earnings?

Across the last 2 reports the average next-day move was ±1.5%, up 0 times and down 2 times.

What is ELVN's implied volatility?

ELVN's at-the-money implied volatility is about 66% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in